HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a $5 price target.
June 07, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arbutus Biopharma and maintained a $5 price target.
The reiteration of a Buy rating and the maintenance of a $5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100